Chiesi Group signs global licensing pact with Key2Brain to advance BBB─crossing therapies for lysosomal storage ...
Chiesi Group, a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases and specialty care, and Key2Brain, a Swedish biotech company develops next generation …